Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study

Por Ou, Huang-Tz, Chang, Kai-Cheng, Li, Chung-Yi, Wu, Jin-Shang
Publicado no Cardiovasc Diabetol (2016)

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second‐ and third‐line antidiabetic drugs in patients with type 2 diabetes

Por Ou, Huang‐Tz, Chang, Kai‐Cheng, Li, Chung‐Yi, Wu, Jin‐Shang
Publicado no Br J Clin Pharmacol (2017)